Jump to content
Sign in to follow this  
Shep

Tsoutsoulas, 2017 Anticholinergic Burden and Cognition in Older Patients With Schizophrenia

Recommended Posts

Shep

Journal of Clinical Psychiatry 2017.  10.4088/JCP.17m11523

 

Anticholinergic Burden and Cognition in Older Patients With Schizophrenia

 

Christopher Tsoutsoulas, BSc (Hons); Benoit H. Mulsant, MD, MS; Sanjeev Kumar, MD; Zaid Ghazala, MBBS; Aristotle N. Voineskos, MD, PhD; Mahesh Menon, PhD; Bruce G. Pollock, MD, PhD; and Tarek K. Rajji, MD

 

Source: Journal of Clinical Psychiatry

 

Anticholinergic Burden and Cognition in Older Patients With Schizophrenia

 

Objective: Older individuals with schizophrenia are at risk of being treated with anticholinergic medications due to the prevalence of medical comorbidities and polypharmacy. High anticholinergic burden impairs cognition and is a risk factor for Alzheimer’s dementia. Thus, we assessed the impact of anticholinergic burden on Alzheimer’s dementia–related and schizophrenia-related cognitive functions in older patients with schizophrenia.

 

Conclusions: High anticholinergic burden contributes to specific cognitive deficits in older individuals with schizophrenia that resemble those commonly observed early in the course of Alzheimer’s dementia. The ACB [Anticholinergic Cognitive Burden] is a potentially useful screening tool that can help identify patients at risk of developing anticholinergic-related cognitive impairment.

 

This article was written up over on the Mad in America site:

 

Anticholinergic Medications Linked to Dementia Similar to Early Alzheimer’s

 

 

Share this post


Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
Sign in to follow this  

×

Important Information

By using this site, you agree to our Terms of Use.